Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2014 1
2015 3
2017 3
2018 2
2020 1
2021 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Plasma CD27, a Surrogate of the Intratumoral CD27-CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma.
Benhamouda N, Sam I, Epaillard N, Gey A, Phan L, Pham HP, Gruel N, Saldmann A, Pineau J, Hasan M, Quiniou V, Nevoret C, Verkarre V, Libri V, Mella S, Granier C, Broudin C, Ravel P, De Guillebon E, Mauge L, Helley D, Jabla B, Chaput N, Albiges L, Katsahian S, Adam J, Mejean A, Adotevi O, Vano YA, Oudard S, Tartour E. Benhamouda N, et al. Among authors: de guillebon e. Clin Cancer Res. 2022 Nov 14;28(22):4983-4994. doi: 10.1158/1078-0432.CCR-22-0905. Clin Cancer Res. 2022. PMID: 36067339
Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.
Combe P, de Guillebon E, Thibault C, Granier C, Tartour E, Oudard S. Combe P, et al. Among authors: de guillebon e. Oncoimmunology. 2015 Mar 19;4(5):e1001236. doi: 10.1080/2162402X.2014.1001236. eCollection 2015 May. Oncoimmunology. 2015. PMID: 26155388 Free PMC article. Review.
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.
Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, Saldmann A, Gey A, Oudard S, Tartour E. Granier C, et al. Among authors: de guillebon e. ESMO Open. 2017 Jul 3;2(2):e000213. doi: 10.1136/esmoopen-2017-000213. eCollection 2017. ESMO Open. 2017. PMID: 28761757 Free PMC article. Review.
Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial.
de Guillebon E, Jimenez M, Mazzarella L, Betsou F, Stadler P, Peták I, Jeannot E, Chanas L, Servant N, Marret G, Duso BA, Legrand F, Kornerup KN, Bernhart SH, Balogh G, Dóczi R, Filotás P, Curigliano G, Bièche I, Guérin J, Dirner A, Neuzillet C, Girard N, Borcoman E, Larbi Chérif L, Tresca P, Roufai DB, Dupain C, Scholl S, André F, Fernandez X, Filleron T, Kamal M, Le Tourneau C. de Guillebon E, et al. ESMO Open. 2021 Jun;6(3):100106. doi: 10.1016/j.esmoop.2021.100106. Epub 2021 Apr 14. ESMO Open. 2021. PMID: 33865192 Free PMC article. Review.
[The "immune checkpoints", how does it work].
Granier C, Soumelis V, Mandavit M, Gibault L, Belazzoug R, de Guillebon E, Badoual C, Tartour E, Roussel H. Granier C, et al. Among authors: de guillebon e. Ann Pathol. 2017 Feb;37(1):18-28. doi: 10.1016/j.annpat.2016.12.007. Epub 2017 Feb 1. Ann Pathol. 2017. PMID: 28160999 French.
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Balmaña J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O'Shaughnessy J, Park YH, Eisen AF, You B, Bourgeois H, Gonçalves A, Kemp Z, Swampillai A, Jankowski T, Sohn JH, Poddubskaya E, Mukhametshina G, Aksoy S, Timcheva CV, Park-Simon TW, Antón-Torres A, John E, Baria K, Gibson I, Gelmon KA; LUCY investigators. Balmaña J, et al. Breast Cancer Res Treat. 2024 Apr;204(2):237-248. doi: 10.1007/s10549-023-07165-x. Epub 2023 Dec 19. Breast Cancer Res Treat. 2024. PMID: 38112922 Free PMC article. Clinical Trial.
Predictors of Mental Health Service Utilization among Frontline Healthcare Workers during the COVID-19 Pandemic.
Starkweather S, DePierro JM, Akhtar S, de Guillebon E, Kaplan C, Kaplan S, Ripp J, Peccoralo L, Feingold J, Feder A, Murrough JW, Pietrzak RH. Starkweather S, et al. Among authors: de guillebon e. Int J Environ Res Public Health. 2023 Mar 30;20(7):5326. doi: 10.3390/ijerph20075326. Int J Environ Res Public Health. 2023. PMID: 37047942 Free PMC article.
[PD-1 and PDL-1 expression in cancer: significance and prognostic value].
Badoual C, Combe P, Gey A, Granier C, Roussel H, De Guillebon E, Oudard S, Tartour E. Badoual C, et al. Among authors: de guillebon e. Med Sci (Paris). 2013 Jun-Jul;29(6-7):570-2. doi: 10.1051/medsci/2013296005. Epub 2013 Jul 12. Med Sci (Paris). 2013. PMID: 23859507 Free article. French. No abstract available.
16 results